TY - JOUR
T1 - Effect of topical anti-inflammatory treatment on the long-term outcome of laser trabeculoplasty
AU - Kim, Yong Y.
AU - Glover, Bernice K.
AU - Shin, Dong H.
AU - Lee, Damho
AU - Frenkel, Ronald E.P.
AU - Abreu, M. Marc
N1 - Funding Information:
Supported in part by a grant from Research to Prevent Blindness, Inc, New York, New York.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1998/11
Y1 - 1998/11
N2 - PURPOSE: To investigate the effect of anti-inflammatory treatment on the long-term outcome of argon laser trabeculoplasty, we extended the short-term study of the Fluorometholone-Laser Trabeculoplasty Study Group. METHODS: Among the chronic open-angle glaucoma patients randomly assigned to the 0.25% fluorometholone or placebo eyedrops four times daily before and after argon laser trabeculoplasty in the Fluorometholone-Laser Trabeculoplasty Study, the long-term records of 27 patients (13 eyes in the fluorometholone group and 14 eyes in the placebo group) were available for our review and analysis. RESULTS: There were no statistically significant differences in the success rate of argon laser trabeculoplasty between the fluorometholone and control groups over the follow-up period of 4.6 ± 3.4 years. CONCLUSION: While it decreased ocular inflammation and discomfort during the early postoperative period, peri-argon laser trabeculoplasty use of a topical corticosteroid did not influence the long-term intraocular pressure outcome of argon laser trabeculoplasty.
AB - PURPOSE: To investigate the effect of anti-inflammatory treatment on the long-term outcome of argon laser trabeculoplasty, we extended the short-term study of the Fluorometholone-Laser Trabeculoplasty Study Group. METHODS: Among the chronic open-angle glaucoma patients randomly assigned to the 0.25% fluorometholone or placebo eyedrops four times daily before and after argon laser trabeculoplasty in the Fluorometholone-Laser Trabeculoplasty Study, the long-term records of 27 patients (13 eyes in the fluorometholone group and 14 eyes in the placebo group) were available for our review and analysis. RESULTS: There were no statistically significant differences in the success rate of argon laser trabeculoplasty between the fluorometholone and control groups over the follow-up period of 4.6 ± 3.4 years. CONCLUSION: While it decreased ocular inflammation and discomfort during the early postoperative period, peri-argon laser trabeculoplasty use of a topical corticosteroid did not influence the long-term intraocular pressure outcome of argon laser trabeculoplasty.
UR - http://www.scopus.com/inward/record.url?scp=0032212683&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032212683&partnerID=8YFLogxK
U2 - 10.1016/S0002-9394(98)00177-9
DO - 10.1016/S0002-9394(98)00177-9
M3 - Article
C2 - 9822239
AN - SCOPUS:0032212683
SN - 0002-9394
VL - 126
SP - 721
EP - 723
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 5
ER -